Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial
Jamil Y, Park D, Verde L, Sherwood M, Tehrani B, Batchelor W, Frampton J, Damluji A, Nanna M. Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial. The American Journal Of Cardiology 2023, 214: 66-76. PMID: 38160927, PMCID: PMC10923116, DOI: 10.1016/j.amjcard.2023.12.045.Peer-Reviewed Original ResearchStable ischemic heart diseaseAnti-anginal agentIntensive medical therapyIschemic heart diseaseMedical therapyQOL metricsHeart diseaseFindings merit further researchMajor adverse cardiovascular eventsAnti-anginal treatmentBARI 2D trialGreater QoL improvementAdverse cardiovascular eventsMyocardial jeopardy indexCardiovascular eventsCause mortalityCardiovascular endpointsClinical confoundersPatient characteristicsDiabetes mellitusHeart failureTherapy intensityClinical outcomesQOL improvementMyocardial infarction